THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345 | -51.0% | 40 | -41.2% | 0.00% | – |
| Q2 2023 | $704 | +70300.0% | 68 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 68 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 68 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -98.1% | 68 | -99.0% | 0.00% | – |
| Q3 2021 | $52,000 | -33.3% | 7,000 | +84.2% | 0.00% | – |
| Q1 2021 | $78,000 | +14.7% | 3,800 | 0.0% | 0.00% | – |
| Q4 2020 | $68,000 | +23.6% | 3,800 | +3.1% | 0.00% | – |
| Q3 2020 | $55,000 | +511.1% | 3,687 | +738.0% | 0.00% | – |
| Q2 2020 | $9,000 | -92.6% | 440 | -91.6% | 0.00% | -100.0% |
| Q1 2020 | $121,000 | -13.6% | 5,250 | -3.0% | 0.00% | 0.0% |
| Q4 2019 | $140,000 | -15.7% | 5,410 | -36.4% | 0.00% | 0.0% |
| Q3 2019 | $166,000 | -9.3% | 8,500 | -24.1% | 0.00% | -50.0% |
| Q2 2019 | $183,000 | -28.0% | 11,199 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $254,000 | – | 11,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |